European Society for Pediatric Dermatology (ESPD)

General Information & Deadlines

1.Abstracts MUST be submitted electronically via the online submission system by the given deadline of Wednesday, 4 January 2023.

Abstracts received via fax, e-mail or received after the deadline will not be accepted and therefore will not be considered for the programme or publication.

2. Abstracts need to be submitted into the following topics:

• ATOPIC AND OTHER DERMATITIDES
• AUTOIMMUNE DISEASES
• BLISTERING/ICHTHYOSIS
• GENODERMATOSES
• INFECTIOUS
• INFLAMMATORY
• MISCELLANEOUS
• NEONATAL
• NEOPLASTIC / TUMORAL
• PIGMENTARY DISORDERS, NAEVI AND OTHER MOSAICS
• TREATMENT
• VASCULAR ANOMALIES & OVERGROWTH

3. A preferred presentation method should be selected during the submission from the following options:

• Oral Presentation
• Poster Presentation 

Please note, oral presentations will be presented mainly in the Oral Communications Parallel Sessions, possibly also in sessions The Training Program and Future Leaders.

4. Once the abstract is “submitted” it can be changed until the Abstract Submission Deadline of 4 January 2023.

5. All abstracts will be reviewed by the ESPD Scientific Committee who will consider its formal aspects and the content. They will decide which abstracts will be accepted.

6. Accepted abstracts will be published in the online Abstract Book. Abstracts not suitable for display will be rejected. Please have your abstract checked for correct spelling, punctuation, grammar and formal structure. The organiser reserves the right to edit abstracts if necessary prior to the publication in the online ESPD Congress Abstract Book.

7. All presenting authors will receive an acceptance/rejection notification via e-mail by 31 January 2023.

8. All presenting authors are obliged to register by Tuesday, 21 February 2023.

European Society for Pediatric Dermatology (ESPD)

General Information & Deadlines

1.Abstracts MUST be submitted electronically via the online submission system by the given deadline of Wednesday, 4 January 2023.

Abstracts received via fax, e-mail or received after the deadline will not be accepted and therefore will not be considered for the programme or publication.

2. Abstracts need to be submitted into the following topics:

• ATOPIC AND OTHER DERMATITIDES
• AUTOIMMUNE DISEASES
• BLISTERING/ICHTHYOSIS
• GENODERMATOSES
• INFECTIOUS
• INFLAMMATORY
• MISCELLANEOUS
• NEONATAL
• NEOPLASTIC / TUMORAL
• PIGMENTARY DISORDERS, NAEVI AND OTHER MOSAICS
• TREATMENT
• VASCULAR ANOMALIES & OVERGROWTH

3. A preferred presentation method should be selected during the submission from the following options:

• Oral Presentation
• Poster Presentation 

Please note, oral presentations will be presented mainly in the Oral Communications Parallel Sessions, possibly also in sessions The Training Program and Future Leaders.

4. Once the abstract is “submitted” it can be changed until the Abstract Submission Deadline of 4 January 2023.

5. All abstracts will be reviewed by the ESPD Scientific Committee who will consider its formal aspects and the content. They will decide which abstracts will be accepted.

6. Accepted abstracts will be published in the online Abstract Book. Abstracts not suitable for display will be rejected. Please have your abstract checked for correct spelling, punctuation, grammar and formal structure. The organiser reserves the right to edit abstracts if necessary prior to the publication in the online ESPD Congress Abstract Book.

7. All presenting authors will receive an acceptance/rejection notification via e-mail by 31 January 2023.

8. All presenting authors are obliged to register by Tuesday, 21 February 2023.

Generalised Pustular Psoriasis (GPP) – a serious rare disease and its treatment


Hereby we cordially invite you to the international webinar on Generalized Pustular Psoriasis, which will take place on June 6th from 4:00 p.m. to 5:00 p.m.

Prof. Wolf (Department of Dermatology, Medical University of Graz, Austria) and Prof. Pavlovsky (Department of Dermatology, University of Tel Aviv, Israel) will discuss the characteristics and challenges of this rare disease and concrete treatment experiences, with a focus on first experiences with spesolimab in this indication.

You can find more information about this event and the link to register in the invitation attached.

Registration:
To access the webinar, please use the following link to register for the event: REGISTRATION

After registration, you will receive an exclusive link to access the webinar

Time: Tuesday, 6th of June 2023 | 16:00-17:00 | Central European Summertime (UTC+2)

Agenda:
16:00-16:05 Welcome and Introduction
16:05-16:20 Pathophysiology, diagnosis and treatment of GPP P. Wolf
16:20-16:35 Practical treatment experiences in GPP L. Pavlovsky
16.35-17:00 Discussion

Prof. Peter Wolf, MD
Peter Wolf, MD, is Professor of Dermatology and Chair of the Department of Dermatology at the Medical University Graz, Austria. Dr. Wolf has long-standing clinical and research interests in inflammatory skin diseases including GPP. He is the principal investigator of numerous previous and ongoing clinical trials investigating novel treatment strategies in skin diseases. As an active member of the PhD programme Molecular Medicine (MOLMED) of the Medical University of Graz his translational research group addresses mechanistic issues of dermatological treatments.

Prof. Lev Pavlovsky
Dr. Lev Pavlovsky, a Clinical Associate Professor of Dermatology at Tel Aviv University‘s Medical School in Israel, is the Director of the Psoriasis Treatment Service at Rabin Medical Center. With particular expertise in immunobiological treatments, he has led several international clinical trials and authored numerous scientific publications and book chapters. Dr. Pavlovsky also serves as a Councilor at the International Psoriasis Council and the National Representative in the SPIN network.

Generalised Pustular Psoriasis (GPP) – a serious rare disease and its treatment


Hereby we cordially invite you to the international webinar on Generalized Pustular Psoriasis, which will take place on June 6th from 4:00 p.m. to 5:00 p.m.

Prof. Wolf (Department of Dermatology, Medical University of Graz, Austria) and Prof. Pavlovsky (Department of Dermatology, University of Tel Aviv, Israel) will discuss the characteristics and challenges of this rare disease and concrete treatment experiences, with a focus on first experiences with spesolimab in this indication.

You can find more information about this event and the link to register in the invitation attached.

Registration:
To access the webinar, please use the following link to register for the event: REGISTRATION

After registration, you will receive an exclusive link to access the webinar

Time: Tuesday, 6th of June 2023 | 16:00-17:00 | Central European Summertime (UTC+2)

Agenda:
16:00-16:05 Welcome and Introduction
16:05-16:20 Pathophysiology, diagnosis and treatment of GPP P. Wolf
16:20-16:35 Practical treatment experiences in GPP L. Pavlovsky
16.35-17:00 Discussion

Prof. Peter Wolf, MD
Peter Wolf, MD, is Professor of Dermatology and Chair of the Department of Dermatology at the Medical University Graz, Austria. Dr. Wolf has long-standing clinical and research interests in inflammatory skin diseases including GPP. He is the principal investigator of numerous previous and ongoing clinical trials investigating novel treatment strategies in skin diseases. As an active member of the PhD programme Molecular Medicine (MOLMED) of the Medical University of Graz his translational research group addresses mechanistic issues of dermatological treatments.

Prof. Lev Pavlovsky
Dr. Lev Pavlovsky, a Clinical Associate Professor of Dermatology at Tel Aviv University‘s Medical School in Israel, is the Director of the Psoriasis Treatment Service at Rabin Medical Center. With particular expertise in immunobiological treatments, he has led several international clinical trials and authored numerous scientific publications and book chapters. Dr. Pavlovsky also serves as a Councilor at the International Psoriasis Council and the National Representative in the SPIN network.